Due to increasing attention to immune checkpoint inhibitors for PCa patients, we analyzed differentially expressed immune checkpoint genes between the two groups and found that patients in the high-risk group tended to express higher levels of LAG3, CTLA4, B7-H3, and B7-H4. The gene discussed is CD276; the disease is posterior cortical atrophy.